This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
26


nanotimes


Companies Facts


cial Officer of The Dow Chemical Company. The Partners have already set priorities for joint potential projects. The emphasis will be on large-scale projects based on nanotechnologies with the aim of attracting cooperation from major corporations and regions in Russia and developing intellectual property.


Furthermore, Dow Chemical achieved sales of $13.8 billion in the fourth quarter of 2010, a 22% increase compared with the same period last year. Double-digit sales increases were also reported in all geographic areas, with the largest gain in North America (25%). On a geographic basis, double-digit volume growth was reported in all geographic areas except Asia Pacific, which was up 9%. Growth in the emerging geographies continued to be robust, par- ticularly for the Performance segments, which re- ported a combined 13% increase in volume. Volume growth also continued to be notable in Latin America and Eastern Europe, both of which reported double- digit increases.


Fourth Quarter 2010 Highlights:


The Company reported earnings of $0.37 per share, or $0.47 per share excluding certain items.(2) This compares with earnings of $0.08 per share in the year-ago period, or $0.18 per share excluding certain items.


Sales of $13.8 billion rose 22 percent versus the same quarter last year. Sales increased double-digits in all geographic areas and in all operating segments except Coatings and Infrastructure, which rose 6 percent.


Health and Agricultural Sciences posted record fourth quarter sales of $1.3 billion. Volume grew 20 percent with gains in every geographic area, led by 35 percent growth in Latin America.


Sales from emerging regions were $4.5 billion, reaching a new quarterly record for the Company. This was driven by volume growth in Thailand (33%), India (31%), Russia (30%), and Brazil (14%).


Net debt to total capitalization declined to 42.6%, 240 basis points below the Company‘s year-end goal. This was primarily due to $1.8 billion of cash flow from operating activities.


Equity earnings reached an all-time quarterly record of $313 million.


EBITDA(4) was $1.9 billion, an increase of 30 per- cent versus the year-ago period.


At the Company level, EBITDA margin expanded more than 200 basis points, representing the seventh consecutive quarter of year-over-year margin ex- pansion. Margin expanded in Plastics by 520 basis points. And Performance Products and Performance Systems together expanded margin by more than 230 basis points. http://www.dow.com


E


.I. DuPont de Nemours and Company, Inc., and Evonik Degussa GmbH of Marl, Germany,


have signed a license agreement which solely grants DuPont worldwide access to the multi-shot or 2K molding technology patented by Evonik for nylon 6,6 and nylon 6. The licensed technology enables the eli- mination of process steps in the production of two-


11-02/03 :: February / March 2011


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95